重症及危重症SARS-CoV-2感染患者接受奈玛特韦/利托那韦治疗后病毒核酸变化的相关因素:单中心回顾性队列研究
该单中心回顾性队列研究纳入2022年12月7日至2023年1月27日在北京大学第一医院诊断为重症或危重症SARS-CoV-2感染且接受奈玛特韦/利托那韦治疗5天的年龄≥16岁患者,共31例重症和37例危重症患者。两组患者从启动奈玛特韦/利托那韦至SARS-CoV-2转阴的中位时间均为6.0天,第15天转阴率分别为93.5%和86.5%。7例(11.3%)患者出现SARS-CoV-2复阳,其中重症1例、危重症6例。多因素Logistic回归显示,淋巴细胞计数降低(OR=0.146,95%CI 0.031-0.689,P=0.015)和降钙素原升高(OR=2.008,95%CI 1.042-3.868,P=0.037)是SARS-CoV-2未转阴或复阳的独立危险因素。持续感染或复阳患者机械通气和有创通气比例显著高于转阴患者(84.6% vs. 38.2%,69.2% vs. 25.5%,均P<0.01),但机械通气和有创通气时间无显著差异。
要点
- 重症及危重症SARS-CoV-2感染患者接受奈玛特韦/利托那韦5天治疗后,低淋巴细胞计数是核酸未转阴或复阳的独立危险因素(OR=0.146,95%CI 0.031-0.689,P=0.015)。
- 高降钙素原是核酸未转阴或复阳的独立危险因素(OR=2.008,95%CI 1.042-3.868,P=0.037)。
- 持续感染或复阳患者机械通气比例84.6% vs. 转阴患者38.2%,有创通气比例69.2% vs. 25.5%,均P<0.01。
- 持续感染或复阳患者ICU入住比例76.9% vs. 转阴患者50.9%,ICU住院时间有延长趋势[13.0(10.3,24.3)天 vs. 11.0(5.3,23.0)天,P>0.05]。
- 重症和危重症患者从启动奈玛特韦/利托那韦至转阴的中位时间均为6.0天,第15天转阴率分别为93.5%和86.5%。
适用人群与场景
- 年龄≥16岁、诊断为重症或危重症SARS-CoV-2感染、且接受奈玛特韦/利托那韦治疗5天的患者,来自北京大学第一医院2022年12月7日至2023年1月27日的住院患者。
处置流程与药物剂量
- 奈玛特韦/利托那韦治疗5天。
研究设计与关键结果
- 单中心回顾性队列研究,共纳入31例重症和37例危重症SARS-CoV-2感染患者。
- 重症和危重症患者从启动奈玛特韦/利托那韦至SARS-CoV-2转阴的中位时间均为6.0天,第15天转阴率分别为93.5%和86.5%。
- 7例(11.3%)患者出现SARS-CoV-2复阳,其中重症1例、危重症6例。
- 将7例复阳和6例未转阴患者与55例持续转阴患者比较,将P<0.10的因素[最低淋巴细胞计数、最高D-二聚体、最高降钙素原、最低Ct值、高血压和冠心病以外的心血管疾病]纳入多因素Logistic回归分析。
- 多因素Logistic回归显示,淋巴细胞计数降低(OR=0.146,95%CI 0.031-0.689,P=0.015)和降钙素原升高(OR=2.008,95%CI 1.042-3.868,P=0.037)是SARS-CoV-2未转阴或复阳的独立危险因素。
- 持续SARS-CoV-2感染或复阳患者机械通气比例显著高于转阴患者(84.6% vs. 38.2%,P<0.01),有创通气比例也显著高于转阴患者(69.2% vs. 25.5%,P<0.01),但机械通气和有创通气时间无显著差异。
- 与转阴患者相比,持续感染或复阳患者入住ICU的比例更高(76.9% vs. 50.9%),ICU住院时间有延长趋势[13.0(10.3,24.3)天 vs. 11.0(5.3,23.0)天,P>0.05]。
证据类型、等级与局限
- 单中心回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,淋巴细胞计数降低和降钙素原升高是重症及危重症SARS-CoV-2感染患者核酸未转阴或复阳的独立危险因素,应关注这些患者的不良预后。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To describe negative conversion and rebound of patients with severe and critical acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection after treatment with Nirmatrelvir/Ritonavir, and to analyze related factors associating with failure of SARS-CoV-2 negative conversion and relapse and prognosis.
METHODS: A single center retrospective cohort study was conducted. Patients aged ≥ 16 years old who were diagnosed with severe or critical SARS-CoV-2 infection and took Nirmatrelvir/Ritonavir for 5 days in Peking University First Hospital from December 7, 2022 to January 27, 2023, were included. General characteristics and clinical data were collected from electronic medical record system. The Kaplan-Meier curve of SARS-CoV-2 negative conversion was drawn. Factors with P < 0.10 were incorporated into multivariate Logistic regression model to analyze the relationship between the factors and persistent nucleic acid positive and rebound.
RESULTS: A total of 31 severe and 37 critical SARS-CoV-2 infection patients were included. The median duration from initiation of Nirmatrelvir/Ritonavir to negative conversion of SARS-CoV-2 for both was 6.0 days, and the negative conversion rate on day 15 was 93.5% and 86.5%, respectively. SARS-CoV-2 rebound was observed in 7 patients (11.3%), among whom were 1 severe patient and 6 critical patients. The above 7 patients with SARS-CoV-2 rebound and 6 patients with failure of SARS-CoV-2 negative conversion were compared with 55 patients with persistent negative conversion. Factors with P < 0.10, including the lowest lymphocyte count (LYM), the highest D-dimer, the highest procalcitonin (PCT), the lowest Ct value, cardiovascular diseases other than hypertension and coronary heart disease, were incorporated into multivariate Logistic regression analysis. The decreased LYM [odds ratio (OR) = 0.146, 95% confidence interval (95%CI) was 0.031-0.689, P = 0.015] and the increased PCT (OR = 2.008, 95%CI was 1.042-3.868, P = 0.037) were revealed to be independent risk factors of the failure of SARS-CoV-2 negative conversion or rebound. The proportion of mechanical ventilation and invasive ventilation were significantly higher in patients with persistent SARS-CoV-2 infection or rebound than those in patients with SARS-CoV-2 negative conversion (84.6% vs. 38.2%, 69.2% vs. 25.5%, both P < 0.01), but no significant difference in mechanical ventilation and invasive ventilation duration was observed. Compared with the patients with SARS-CoV-2 negative conversion, more patients with persistent SARS-CoV-2 infection or rebound were admitted to intensive care unit (ICU, 76.9% vs. 50.9%), and length of ICU stay in patients with persistent SARS-CoV-2 infection or rebound tended to be longer [days: 13.0 (10.3, 24.3) vs. 11.0 (5.3, 23.0), P > 0.05].
CONCLUSIONS: The decreased LYM and increased PCT are independent risk factors for the failure of SARS-CoV-2 negative conversion or rebound in patients with severe and critical SARS-CoV-2 infection. Attention should be paid to these patients for their poor prognosis.
参考来源
- Yan M, Xie M, Zhu S, et al. [Related factors of viral nucleic acid change in critically ill patients with SARS-CoV-2 infection after treatment with Nirmatrelvir/Ritonavir: a single center retrospective cohort study]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2023. PMID: 37987124. doi:10.3760/cma.j.cn121430-20230718-00523
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。